Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | CYP2C8 | P10632 | 4/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL934374 | 0.91 | PSMB5 (0.47) | PSMB5PTGDR2PDK1CYP2C8CYP2C19 | |
| SCHEMBL935045 | 0.89 | PTGDR2 (0.48) | PTGDR2CYP2C8CYP2C19CYP2C9LTB4R2 | |
| SCHEMBL934660 | 0.89 | LTB4R2 (0.48) | PTGDR2CYP2C8CYP2C19CYP2C9LTB4R2 | |
| SCHEMBL934632 | 0.83 | PTGDR2 (0.47) | PTGDR2PDK1CYP2C8CYP2C19CYP2C9 | |
| SCHEMBL933501 | 0.83 | PTGDR2 (0.44) | PTGDR2CYP2C8CYP2C19CYP2C9LTB4R2 | |
| SCHEMBL934274 | 0.81 | PTGDR2 (0.57) | PTGDR2PDK1CYP2C8CYP2C19CYP2C9 | |
| SCHEMBL934744 | 0.81 | PTGDR2 (0.44) | PTGDR2CYP2C8CYP2C19CYP2C9LTB4R2 | |
| SCHEMBL2681123 | 0.81 | PTGDR2 (0.51) | PTGDR2CYP2C8CYP2C19CYP2C9LTB4R2 | |
| SCHEMBL933632 | 0.80 | LTB4R2 (0.49) | PTGDR2CYP2C8CYP2C19CYP2C9LTB4R2 | |
| SCHEMBL933912 | 0.80 | STAT3 (0.45) | PTGDR2CYP2C8CYP2C19CYP2C9LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454243-A2 | TETRAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-05-23 | — | — | EP | disclosed |
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2012-05-10 | — | — | US | disclosed |
| WO-2011006935-A2 | TETRAZOLE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115869-A1 | TETRAZOLE DERIVATIVES | TSLP, IL5, CMA1 | PSMB5 379/4885PTGDR2 548/4885PDK1 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.